Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03554707Early Phase 1Withdrawn

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Role: lead

NCT02354547Phase 1Suspended

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Role: lead

NCT02340117Phase 2Active Not Recruiting

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Role: lead

NCT02340156Phase 2Terminated

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Role: lead

NCT01517464Phase 1Completed

A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors

Role: lead

NCT00470613Phase 1Completed

Safety Study of Infusion of SGT-53 to Treat Solid Tumors

Role: lead

All 6 trials loaded